Dose-dense Weekly Paclitaxel Does Not Increase PFS
(March 3, 2016) In a study published in the New England Journal of Medicine this week, researchers report that a dose-dense weekly paclitaxel regimen failed to improve progression-free survival in advanced ovarian cancer versus a conventional regimen and optional bevacizumab (Avastin).
Patients treated with weekly paclitaxel plus carboplatin had a median PFS of 14.7 months compared with 14.0 months among patients assigned to paclitaxel and carboplatin every 3 weeks. The outcome contrasted with that of a previous Japanese study showing a significant survival benefit in ovarian cancer treated with dose-dense weekly paclitaxel.
Read an article on this study in MedPage Today; and read the study abstract.